company background image
TKPH.F logo

Takeda Pharmaceutical OTCPK:TKPH.F Stock Report

Last Price

US$28.45

Market Cap

US$45.4b

7D

-1.7%

1Y

-13.1%

Updated

26 Mar, 2024

Data

Company Financials +

Takeda Pharmaceutical Company Limited

OTCPK:TKPH.F Stock Report

Market Cap: US$45.4b

TKPH.F Stock Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.

TKPH.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance1/6
Financial Health3/6
Dividends3/6

Takeda Pharmaceutical Company Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Takeda Pharmaceutical
Historical stock prices
Current Share PriceJP¥28.45
52 Week HighJP¥34.47
52 Week LowJP¥26.25
Beta0.54
1 Month Change-0.63%
3 Month Change3.08%
1 Year Change-13.10%
3 Year Change-21.95%
5 Year Change-29.68%
Change since IPO-23.21%

Recent News & Updates

Recent updates

Shareholder Returns

TKPH.FUS PharmaceuticalsUS Market
7D-1.7%-0.2%0.6%
1Y-13.1%23.9%29.5%

Return vs Industry: TKPH.F underperformed the US Pharmaceuticals industry which returned 23.1% over the past year.

Return vs Market: TKPH.F underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is TKPH.F's price volatile compared to industry and market?
TKPH.F volatility
TKPH.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: TKPH.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine TKPH.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
178149,095Christophe Weberhttps://www.takeda.com

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands.

Takeda Pharmaceutical Company Limited Fundamentals Summary

How do Takeda Pharmaceutical's earnings and revenue compare to its market cap?
TKPH.F fundamental statistics
Market capUS$45.35b
Earnings (TTM)US$1.18b
Revenue (TTM)US$27.50b

38.6x

P/E Ratio

1.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TKPH.F income statement (TTM)
RevenueJP¥4.17t
Cost of RevenueJP¥1.34t
Gross ProfitJP¥2.82t
Other ExpensesJP¥2.65t
EarningsJP¥178.22b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 09, 2024

Earnings per share (EPS)113.59
Gross Margin67.76%
Net Profit Margin4.27%
Debt/Equity Ratio69.2%

How did TKPH.F perform over the long term?

See historical performance and comparison

Dividends

4.3%

Current Dividend Yield

161%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.